Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and ...

Can AI be used in anti-VEGF selection process and in the detection ... in retinal fluid volume quantification from repeated self-imaging with home OCT in eyes with neovascular age-related macular ...

Ocular Therapeutix (OCUL) stock rises as its Phase 3 trial for lead asset Axpaxli in wet AMD nears enrollment target. Read ...

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...